737
Participants
Start Date
May 31, 2014
Primary Completion Date
November 18, 2016
Study Completion Date
November 18, 2016
Levothyroxine
The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Placebo
Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow
University of Glasgow
OTHER
University College Cork
OTHER
University of Bern
OTHER
Leiden University Medical Center
OTHER
NHS Greater Glasgow and Clyde
OTHER